NVP-ACC789

SKU: orb1304179

Description

ACC-789 (NVP-ACC789, ZK-202650) is a potent, selective, and orally bioavailable inhibitor targeting VEGF receptor tyrosine kinases. It is utilized in cancer research, particularly in studies of angiogenesis, and has demonstrated activity in both in vitro cellular assays and in vivo tumor models.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 300842-64-2
• MW: 405.29
• Purity: 99.63% (May vary between batches)
• Formula: C₂₁H₁₇BrN₄
• SMILES: Cc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1Br
• Target: VEGFR,PDGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.93 mM);DMSO:60 mg/mL (148.04 mM)

Bioactivity

• Target IC50:
  PDGFRβ:1.4 μM|VEGFR1 (human):0.38μM|VEGFR3:0.18μM|VEGFR2 (mouse):0.23μM|VEGFR2 (human):0.02μM

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Platelet-derived growth factor receptor, NVP-ACC 789, NVPACC789, NVP-ACC789, NVP-ACC-789, NVP ACC789, ACC789, ACC-789, ACC 789, ZK202650, ZK-202650, ZK 202650, PDGFR, PDGFRβ, VEGFR

Compound Identifiers

PubChem CID

6918616